Shopping Cart 0
Cart Subtotal
USD 0

MIDDLE EAST AND AFRICA ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 1500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 2200
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

MARKET OUTLOOK

Triton's report has on the Alzheimer's disease therapeutics and diagnostics market in the Middle East & Africa has determined the market to proliferate at a CAGR of 6.65% during the forecast period 2019-2027.

Turkey, South Africa, Saudi Arabia, United Arab Emirates and countries in rest of the Middle East & Africa constitute the Middle East & Africa Alzheimer's disease therapeutics and diagnostics market.

The rise of the Alzheimer's disease therapeutics & diagnostics market in Middle East & Africa is witnessed due to private investments to develop neurodegenerative disease therapies and government plans supporting advancements in neurodegenerative disease treatment. The growth in the demand for drug development and diagnostic tests can be attributed to the sudden upsurge in Alzheimer's cases being registered in the region. Moreover, substantial investments made by the government in research for neurodegenerative diseases and the pharmaceutical sector act as a key driver for the Alzheimer's disease therapeutics and diagnostics market in the region.

In-vitro diagnostics are medical devices that are used to perform tests on samples (e.g. blood or tissue) that have been derived from the human body. IVDs can help detect diseases or other conditions; they can be used for monitoring an individual's overall health for the cure, treatment or prevention of diseases. IVDs also have applications in precision medicine. Biomarkers are the tests performed most often in cases of Alzheimer's and other forms of dementia. Several private firms and government organizations are investing for the advancement in biomarkers for Alzheimer's treatment. However, the high cost of therapies used for the treatment of Alzheimer's disease is one of the major factors impeding the growth of global Alzheimer's disease therapeutics and diagnostics market during the forecast period.

 

 

COMPETITIVE OUTLOOK

Pfizer, Inc., F. Hoffmann-La Roche AG, GE Healthcare, AbbVie, Inc., Biogen, Inc., Baxter International, Inc., Piramal Enterprises, Ltd., Sun Pharma, Siemens Medical Solutions and Merck and Co. are some of the prominent companies in the Alzheimer's disease therapeutics and diagnostics market.

READ MORE

Table Of Content

Scope

TABLE OF CONTENTS

1. MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET-SUMMARY

2. INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER'S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. THREATS OF SUBSTITUTE PRODUCT

2.2.3. BARGAINING POWER OF BUYER

2.2.4. BARGAINING POWER OF SUPPLIER

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. ETYMOLOGY

2.5. PARENT MARKET OUTLOOK

2.6. STRATEGIC BUYING CRITERIA OUTLOOK

2.7. INVESTMENTS OUTLOOK

2.8. KEY FINDINGS

2.9. INDUSTRY STRUCTURE

2.9.1. RESEARCH & DEVELOPMENT

2.9.2. MANUFACTURING

2.9.3. RAW MATERIALS

2.9.4. END-USER

2.9.5. WHOLESALERS

2.10. ALZHEIMER'S DISEASE ETIOLOGY

2.11. PIPELINE OUTLOOK

2.12. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE

2.13. MARKET DRIVERS

2.13.1. GROWTH OF ALZHEIMER'S DISEASE

2.13.2. RISE IN GERIATRIC POPULATION

2.13.3. SUBSTANTIAL INVESTMENTS BY GOVERNMENT IN RESEARCH

2.14. MARKET RESTRAINTS

2.14.1. STRINGENT GOVERNMENT REGULATIONS

2.14.2. HIGH TREATMENT COSTS OF ALZHEIMER'S DISEASE

2.15. MARKET OPPORTUNITIES

2.15.1. IN-VITRO DIAGNOSTIC TECHNIQUES ARE A BOON TO THE MARKET

2.15.2. R&D INVESTMENT IN PERSONALIZED MEDICINES IS INCREASING

2.16. MARKET CHALLENGES

2.16.1. LESS AWARENESS CONCERNING NEW THERAPIES IN ALZHEIMER'S DISEASE

2.16.2. VERY FEW SKILLED PROFESSIONALS PERTAINING TO THE TREATMENT OF ALZHEIMER'S DISEASE

3. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK-BY THERAPEUTICS AND DIAGNOSTICS

3.1. THERAPEUTICS

3.1.1. THERAPEUTICS BY DRUGS

3.1.1.1. MARKETED DRUGS

3.1.1.2. PIPELINE DRUGS

3.1.2. THERAPEUTICS BY DISEASE STAGE

3.1.2.1. LATE STAGE: SEVERE AD

3.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.1.2.3. PRODROMAL STAGE

3.1.3. THERAPEUTICS BY GENERIC AND BRANDED

3.1.3.1. BRANDED

3.1.3.2. GENERIC

3.2. DIAGNOSTICS

3.2.1. LUMBAR PUNCTURE TEST

3.2.2. POSITRON EMISSION TOMOGRAPHY

3.2.3. ELECTROENCEPHALOGRAPHY

3.2.4. MAGNETIC RESONANCE IMAGING

3.2.5. COMPUTED TOMOGRAPHY

3.2.6. OTHER DIAGNOSTICS

4. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET-REGIONAL OUTLOOK

4.1.1. COUNTRY ANALYSIS

4.1.1.1. SAUDI ARABIA

4.1.1.2. TURKEY

4.1.1.3. UNITED ARAB EMIRATES

4.1.1.4. SOUTH AFRICA

4.1.1.5. REST OF MIDDLE EAST AND AFRICA

5. COMPETITIVE LANDSCAPE

5.1. ABBVIE, INC.

5.2. BAXTER INTERNATIONAL, INC.

5.3. BIOGEN, INC.

5.4. F. HOFFMANN-LA ROCHE AG

5.5. GE HEALTHCARE

5.6. MERCK AND CO.

5.7. PFIZER, INC.

5.8. PIRAMAL ENTERPRISES, LTD.

5.9. SIEMENS MEDICAL SOLUTIONS

5.10. SUN PHARMA

6. METHODOLOGY AND SCOPE

6.1. RESEARCH SCOPE

6.2. SOURCES OF DATA

6.3. RESEARCH METHODOLOGY

 

 

TABLE LIST

TABLE 1 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO THE ALZHEIMER'S DISEASE

TABLE 3 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY GENERIC AND BRANDED, 2019-2027 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY TYPES, 2019-2027 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

 

 

 

 

 

 

 

 

FIGURE LIST

FIGURE 1 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 3 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 4 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 5 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 6 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 7 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 8 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 9 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 10 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 11 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 12 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 13 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 14 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 15 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 16 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 17 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 18 SAUDI ARABIA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 19 TURKEY ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 20 UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 21 SOUTH AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 22 REST OF MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)


List Of Figure

FIGURE LIST

FIGURE 1 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 3 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 4 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 5 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 6 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 7 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 8 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 9 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 10 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 11 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 12 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 13 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 14 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 15 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 16 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 17 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 18 SAUDI ARABIA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 19 TURKEY ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 20 UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 21 SOUTH AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 22 REST OF MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)


List Of Table

TABLE LIST

TABLE 1 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO THE ALZHEIMER'S DISEASE

TABLE 3 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY GENERIC AND BRANDED, 2019-2027 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY TYPES, 2019-2027 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

1. ABBVIE, INC.

2. BAXTER INTERNATIONAL, INC.

3. BIOGEN, INC.

4. F. HOFFMANN-LA ROCHE AG

5. GE HEALTHCARE

6. MERCK AND CO.

7. PFIZER, INC.

8. PIRAMAL ENTERPRISES, LTD.

9. SIEMENS MEDICAL SOLUTIONS

10. SUN PHARMA

MARKET OUTLOOK

Triton's report has on the Alzheimer's disease therapeutics and diagnostics market in the Middle East & Africa has determined the market to proliferate at a CAGR of 6.65% during the forecast period 2019-2027.

Turkey, South Africa, Saudi Arabia, United Arab Emirates and countries in rest of the Middle East & Africa constitute the Middle East & Africa Alzheimer's disease therapeutics and diagnostics market.

The rise of the Alzheimer's disease therapeutics & diagnostics market in Middle East & Africa is witnessed due to private investments to develop neurodegenerative disease therapies and government plans supporting advancements in neurodegenerative disease treatment. The growth in the demand for drug development and diagnostic tests can be attributed to the sudden upsurge in Alzheimer's cases being registered in the region. Moreover, substantial investments made by the government in research for neurodegenerative diseases and the pharmaceutical sector act as a key driver for the Alzheimer's disease therapeutics and diagnostics market in the region.

In-vitro diagnostics are medical devices that are used to perform tests on samples (e.g. blood or tissue) that have been derived from the human body. IVDs can help detect diseases or other conditions; they can be used for monitoring an individual's overall health for the cure, treatment or prevention of diseases. IVDs also have applications in precision medicine. Biomarkers are the tests performed most often in cases of Alzheimer's and other forms of dementia. Several private firms and government organizations are investing for the advancement in biomarkers for Alzheimer's treatment. However, the high cost of therapies used for the treatment of Alzheimer's disease is one of the major factors impeding the growth of global Alzheimer's disease therapeutics and diagnostics market during the forecast period.

 

 

COMPETITIVE OUTLOOK

Pfizer, Inc., F. Hoffmann-La Roche AG, GE Healthcare, AbbVie, Inc., Biogen, Inc., Baxter International, Inc., Piramal Enterprises, Ltd., Sun Pharma, Siemens Medical Solutions and Merck and Co. are some of the prominent companies in the Alzheimer's disease therapeutics and diagnostics market.

READ MORE

Scope

TABLE OF CONTENTS

1. MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET-SUMMARY

2. INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER'S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. THREATS OF SUBSTITUTE PRODUCT

2.2.3. BARGAINING POWER OF BUYER

2.2.4. BARGAINING POWER OF SUPPLIER

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. ETYMOLOGY

2.5. PARENT MARKET OUTLOOK

2.6. STRATEGIC BUYING CRITERIA OUTLOOK

2.7. INVESTMENTS OUTLOOK

2.8. KEY FINDINGS

2.9. INDUSTRY STRUCTURE

2.9.1. RESEARCH & DEVELOPMENT

2.9.2. MANUFACTURING

2.9.3. RAW MATERIALS

2.9.4. END-USER

2.9.5. WHOLESALERS

2.10. ALZHEIMER'S DISEASE ETIOLOGY

2.11. PIPELINE OUTLOOK

2.12. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE

2.13. MARKET DRIVERS

2.13.1. GROWTH OF ALZHEIMER'S DISEASE

2.13.2. RISE IN GERIATRIC POPULATION

2.13.3. SUBSTANTIAL INVESTMENTS BY GOVERNMENT IN RESEARCH

2.14. MARKET RESTRAINTS

2.14.1. STRINGENT GOVERNMENT REGULATIONS

2.14.2. HIGH TREATMENT COSTS OF ALZHEIMER'S DISEASE

2.15. MARKET OPPORTUNITIES

2.15.1. IN-VITRO DIAGNOSTIC TECHNIQUES ARE A BOON TO THE MARKET

2.15.2. R&D INVESTMENT IN PERSONALIZED MEDICINES IS INCREASING

2.16. MARKET CHALLENGES

2.16.1. LESS AWARENESS CONCERNING NEW THERAPIES IN ALZHEIMER'S DISEASE

2.16.2. VERY FEW SKILLED PROFESSIONALS PERTAINING TO THE TREATMENT OF ALZHEIMER'S DISEASE

3. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK-BY THERAPEUTICS AND DIAGNOSTICS

3.1. THERAPEUTICS

3.1.1. THERAPEUTICS BY DRUGS

3.1.1.1. MARKETED DRUGS

3.1.1.2. PIPELINE DRUGS

3.1.2. THERAPEUTICS BY DISEASE STAGE

3.1.2.1. LATE STAGE: SEVERE AD

3.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.1.2.3. PRODROMAL STAGE

3.1.3. THERAPEUTICS BY GENERIC AND BRANDED

3.1.3.1. BRANDED

3.1.3.2. GENERIC

3.2. DIAGNOSTICS

3.2.1. LUMBAR PUNCTURE TEST

3.2.2. POSITRON EMISSION TOMOGRAPHY

3.2.3. ELECTROENCEPHALOGRAPHY

3.2.4. MAGNETIC RESONANCE IMAGING

3.2.5. COMPUTED TOMOGRAPHY

3.2.6. OTHER DIAGNOSTICS

4. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET-REGIONAL OUTLOOK

4.1.1. COUNTRY ANALYSIS

4.1.1.1. SAUDI ARABIA

4.1.1.2. TURKEY

4.1.1.3. UNITED ARAB EMIRATES

4.1.1.4. SOUTH AFRICA

4.1.1.5. REST OF MIDDLE EAST AND AFRICA

5. COMPETITIVE LANDSCAPE

5.1. ABBVIE, INC.

5.2. BAXTER INTERNATIONAL, INC.

5.3. BIOGEN, INC.

5.4. F. HOFFMANN-LA ROCHE AG

5.5. GE HEALTHCARE

5.6. MERCK AND CO.

5.7. PFIZER, INC.

5.8. PIRAMAL ENTERPRISES, LTD.

5.9. SIEMENS MEDICAL SOLUTIONS

5.10. SUN PHARMA

6. METHODOLOGY AND SCOPE

6.1. RESEARCH SCOPE

6.2. SOURCES OF DATA

6.3. RESEARCH METHODOLOGY

 

 

TABLE LIST

TABLE 1 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO THE ALZHEIMER'S DISEASE

TABLE 3 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY GENERIC AND BRANDED, 2019-2027 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY TYPES, 2019-2027 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

 

 

 

 

 

 

 

 

FIGURE LIST

FIGURE 1 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 3 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 4 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 5 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 6 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 7 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 8 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 9 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 10 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 11 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 12 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 13 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 14 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 15 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 16 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 17 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 18 SAUDI ARABIA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 19 TURKEY ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 20 UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 21 SOUTH AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 22 REST OF MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)


List Of Figure

FIGURE LIST

FIGURE 1 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 3 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 4 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 5 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 6 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 7 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 8 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 9 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 10 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 11 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 12 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 13 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 14 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 15 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 16 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 17 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 18 SAUDI ARABIA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 19 TURKEY ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 20 UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 21 SOUTH AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 22 REST OF MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)


List Of Table

TABLE LIST

TABLE 1 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO THE ALZHEIMER'S DISEASE

TABLE 3 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY GENERIC AND BRANDED, 2019-2027 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY TYPES, 2019-2027 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

1. ABBVIE, INC.

2. BAXTER INTERNATIONAL, INC.

3. BIOGEN, INC.

4. F. HOFFMANN-LA ROCHE AG

5. GE HEALTHCARE

6. MERCK AND CO.

7. PFIZER, INC.

8. PIRAMAL ENTERPRISES, LTD.

9. SIEMENS MEDICAL SOLUTIONS

10. SUN PHARMA